Kodiak Reports Q3 Loss and Positive Phase 3 Retinal-Drug Data
Kodiak Sciences reported third-quarter 2026 results for the period ended September 30, 2026, including a net loss of $66.2 million and GAAP loss of $1.05 per share. The company said Zenkuda and tabirafusp-ted each achieved key Phase 3 endpoints, with 54% of Zenkuda patients reaching 6-month dosing in the DAYBREAK study. Kodiak raised $69 million after quarter-end, held $88.7 million in cash and cash equivalents at quarter-end, and expects to submit a Zenkuda BLA in the fourth quarter of 2026 while targeting December 2026 data for KSI-101.
Why it matters
The clinical results advance Kodiak's lead programs toward regulatory submissions, while the $69 million equity financing adds funding but increases the number of shares outstanding. The company expects its cash and cash equivalents to support current and planned operations into 2027.
Key facts
- 1Kodiak posted a third-quarter 2026 net loss of $66.2 million, or $1.05 per share on a basic and diluted basis. prnewswire.com
- 2Zenkuda met the DAYBREAK Phase 3 primary endpoint, and 54% of patients were on 6-month dosing under the study criteria. prnewswire.com
- 3Tabirafusp-ted achieved its vision primary endpoint with a p-value of 0.0036 and its anatomical key secondary endpoint with a p-value of <0.0001. prnewswire.com
- 4Kodiak had $88.7 million of cash and cash equivalents at the end of the third quarter and subsequently raised aggregate net proceeds of $69 million through its ATM equity offering. prnewswire.com
- 5Kodiak plans to submit a multi-indication BLA for Zenkuda in the fourth quarter of 2026 and expects initial KSI-101 topline results in December 2026. sec.gov
Open questions
- The earnings-surprise comparison is inconsistent across materials: one says the GAAP loss of $1.05 per share beat estimates by $0.01, while another says it exceeded a consensus loss estimate of $1.00 per share.
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.